You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Early Disease Considerations in HER2-Positive Breast Cancer

  • Authors: Ciara O'Sullivan, MD; Nadine Tung, MD; Ana Garrido-Castro, MD; Reshma L. Mahtani, DO
  • CME / ABIM MOC / CE Released: 12/5/2022
  • Valid for credit through: 12/5/2023
Start Activity

  • Credits Available

    Physicians - maximum of 1.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.50 ABIM MOC points

    Nurses - 1.50 ANCC Contact Hour(s) (1.5 contact hours are in the area of pharmacology)

    Pharmacists - 1.50 Knowledge-based ACPE (0.150 CEUs)

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematologists/oncologists, pathologists, surgeons, nurse practitioners, physician assistants, pharmacists, and nurses.

The goal of this activity is for the learners to be better able to understand the spectrum of breast cancer treatment and provide strategies that can help translate data updates to improvements in patient care.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical data associated with treatment strategies for pre-operative treatment of HER2-positive breast cancer
    • Definition of high-risk residual HER2-positive breast cancer
    • Escalation and de-escalation strategies in HER2-positive early breast cancer
  • Demonstrate greater confidence in their ability to
    • Incorporate strategies to improve outcomes in breast cancer care


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


Faculty

  • Ciara O'Sullivan, MD

    Consultant of Medical Oncology
    Mayo Clinic
    Rochester, Minnesota

    Disclosures

    Ciara O'Sullivan, MD, has the following relevant financial relationships:
    Consultant or advisor for: Seagen, Inc.
    Research funding from: AACRU; Bavarian Nordic; Biovica; Lilly; Minnemarita Therapeutics; Nference Inc.; Seagen, Inc; Sermonix Pharmaceuticals

  • Nadine Tung, MD

    Professor of Medicine
    Harvard Medical School and Director
    Breast Medical Oncology
    Beth Israel Deaconess Medical Center
    Boston, Massachusetts

    Disclosures

    Nadine Tung, MD, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca
    Research funding from: AstraZeneca
    Contracted researcher for: AstraZeneca

  • Ana Garrido-Castro, MD

    Instructor in Medicine
    Harvard Medical School
    Medical Oncologist
    Dana Farber/Brigham and Women's Cancer Center
    Boston, Massachusetts

    Disclosures

    Ana Garrido-Castro, MD, has the following relevant financial relationships:
    Research funding from: AstraZeneca; Gilead Sciences; Immunomedics; Merck

  • Reshma L. Mahtani, DO

    Chief of Breast Medical Oncology
    Miami Cancer Institute
    Baptist Health South Florida
    Plantation, Florida 

    Disclosures

    Reshma L. Mahtani, DO, has the following relevant financial relationships:
    Consultant or advisor for: Agendia; Amgen; AstraZeneca; Biotheranostics; Daiichi Sankyo; Eisai; Genentech; Gilead; Lilly; Merck; Novartis; Pfizer; PUMA; Sanofi; Seagen, Inc.
    Research funding from: Agendia; AstraZeneca; Genentech; Veru

Editor

  • Davecia R. Cameron, MS

    Medical Education Director, Medscape, LLC

    Disclosures

    Davecia R. Cameron, MS, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 1.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.50 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 1.50 contact hour(s) (0.150 CEUs) (Universal Activity Number: JA0007105-0000-22-309-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Early Disease Considerations in HER2-Positive Breast Cancer

Authors: Ciara O'Sullivan, MD; Nadine Tung, MD; Ana Garrido-Castro, MD; Reshma L. Mahtani, DOFaculty and Disclosures

CME / ABIM MOC / CE Released: 12/5/2022

Valid for credit through: 12/5/2023

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Optimizing Pre-Operative Treatment of HER2-Positive Breast Cancer

Drs Mahatani and Garrido-Castro cover the data for optimizing pre-operative treatment for patients with HER2-positive breast cancer.
Reshma L. Mahtani, DO; Ana Garrido-Castro, MD

High-Risk Residual HER2-Positive Breast Cancer: Current and Future Directions (TDM1 and Beyond)

Dr Ciara O'Sullivan delves into the data for management of high-risk residual HER2-positive breast cancer.
Ciara O'Sullivan, MD

Right-Sizing Therapy for Early-Stage HER2-Positive Breast Cancer​

How do you find the right therapy for early-stage HER2-positive breast cancer? Dr Nadine Tung explores the data.
Nadine Tung, MD
 

Educational Impact Challenge

The goal of this activity is for the learners to be better able to understand the spectrum of breast cancer treatment and provide strategies that can help translate data updates to improvements in patient care.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print